Overlooked from yesterday??
Our Phase II study of patients with mCRC was launched in July 2025, to evaluate the safety and efficacy of leronlimab (350 mg versus 700 mg) added to a backbone of Bevacizumab and Tipiracil.
___
Google says:
Bevacizumab (brand name Avastin) is a targeted therapy drug, a monoclonal antibody that stops tumors from growing new blood vessels (angiogenesis) by blocking VEGF, effectively starving them of nutrients and oxygen, used for cancers like colorectal, lung, kidney, brain, and ovarian cancer, and also for eye conditions like wet AMD and diabetic macular edema. Administered intravenously or via eye injection, common side effects include nosebleeds, high blood pressure, and headaches, while serious risks involve severe bleeding, heart failure, and infusion reactions, requiring careful monitoring.
_____
*Tipiracil is a chemotherapy drug component used in combination with trifluridine in the medication branded as Lonsurf®. It is primarily used to treat certain types of advanced colorectal and stomach cancers that have already been treated with other therapies.
*Trifluridine:
Oral Tablets (Combination with Tipiracil): When combined with tipiracil and marketed as Lonsurf®, it is an oral chemotherapy used to treat metastatic colorectal cancer and metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma in patients who have been previously treated with other therapies. Tipiracil prevents the rapid breakdown of trifluridine, allowing it to work longer in the body against cancer cells.
*** how about just this 1 notice from Mayo site on these 2 drugs ***
"Wear gloves when handling this medicine.
Wash your hands after handling the tablets."
Yea, but let it touch your tongue & surely swallowing it within a split second.
___
Cytodyn Dec. Letter continues:
Early results from the mCRC trial have been very encouraging, and we have already submitted abstracts for at least two presentations on the CRC study in 2026– one presentation on biomarker results, and a second focused on clinical outcomes.
___
Think Cytodyn is excited due to Avastin ? Lol
News reads as Abstracts will also show LL head to head & or against combo Tipiracil / Trifluridine.
Showing early proof of LL Stand Alone & Prime n Pair ??
All reads to me that the overall message from Dr. J is:
Either way, you shareholders are reading the start of a new SOC via Leronlimab.
Our Phase II study of patients with mCRC was launched in July 2025, to evaluate the safety and efficacy of leronlimab (350 mg versus 700 mg) added to a backbone of Bevacizumab and Tipiracil.
___
Google says:
Bevacizumab (brand name Avastin) is a targeted therapy drug, a monoclonal antibody that stops tumors from growing new blood vessels (angiogenesis) by blocking VEGF, effectively starving them of nutrients and oxygen, used for cancers like colorectal, lung, kidney, brain, and ovarian cancer, and also for eye conditions like wet AMD and diabetic macular edema. Administered intravenously or via eye injection, common side effects include nosebleeds, high blood pressure, and headaches, while serious risks involve severe bleeding, heart failure, and infusion reactions, requiring careful monitoring.
_____
*Tipiracil is a chemotherapy drug component used in combination with trifluridine in the medication branded as Lonsurf®. It is primarily used to treat certain types of advanced colorectal and stomach cancers that have already been treated with other therapies.
*Trifluridine:
Oral Tablets (Combination with Tipiracil): When combined with tipiracil and marketed as Lonsurf®, it is an oral chemotherapy used to treat metastatic colorectal cancer and metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma in patients who have been previously treated with other therapies. Tipiracil prevents the rapid breakdown of trifluridine, allowing it to work longer in the body against cancer cells.
*** how about just this 1 notice from Mayo site on these 2 drugs ***
"Wear gloves when handling this medicine.
Wash your hands after handling the tablets."
Yea, but let it touch your tongue & surely swallowing it within a split second.
___
Cytodyn Dec. Letter continues:
Early results from the mCRC trial have been very encouraging, and we have already submitted abstracts for at least two presentations on the CRC study in 2026– one presentation on biomarker results, and a second focused on clinical outcomes.
___
Think Cytodyn is excited due to Avastin ? Lol
News reads as Abstracts will also show LL head to head & or against combo Tipiracil / Trifluridine.
Showing early proof of LL Stand Alone & Prime n Pair ??
All reads to me that the overall message from Dr. J is:
Either way, you shareholders are reading the start of a new SOC via Leronlimab.
7
